Caliper Life Sciences Launches Comprehensive Drug Discovery and Development Services Business
Caliper Life Sciences, Inc. unveiled Caliper Discovery Alliances & services (CDAS), the newly-formed services organization created from the integration of NovaScreen Biosciences, a provider of in vitro discovery services, and Xenogen Biosciences, a provider of in vivo discovery services. NovaScreen was acquired by Caliper in October, 2005 and Xenogen was acquired by Caliper in August, 2006.
According to the company, through these key acquisitions, Caliper has assembled a wide range of in vitro and in vivo products and services that enable pharmaceutical companies to reduce costs while increasing the pace and clinical relevance of drug research. Caliper's strategy is to provide its customers with the tools for building an "In Vitro-In Vivo Bridge" [I-I Bridge] to address the growing pressure on the pharmaceutical industry to find new, effective drugs while minimizing the risk of adverse effects of those drugs.
Immunology research is one therapeutic area where CDAS offers assays that span the I-I Bridge. For example, a client's compound can be tested in vitro, using cell-based assays, for the compound's ability to stimulate the production of key proteins that signal an immune response. The same cell-based models have been incorporated into mice, so that in vivo compound profiling, phenotyping, or biophotonic imaging studies can be performed. By using the same cell model both in vitro and in vivo, scientists can better correlate the sets of results.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
